Drug Trial Radar · NCT06658353
Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Mar 17, 2025
Primary completion
Dec 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Jiangsu vcare pharmaceutical technology co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Oct 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.
Conditions
- Locally Advanced Solid Tumor
Interventions
VC004 CapsulesDrug
VC004 Capsules BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate(ORR)Time frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.